**Core tip:** New concepts have emerged in the management of inflammatory bowel disease, such as the "treat-to-target" concept in which mucosal healing plays a key role in the evolution, risk of recurrence and need for surgery. Endoscopy is essential for the assessment of mucosal inflammation and plays a pivotal role in the analysis of mucosal healing in patients with inflammatory bowel disease (IBD) and in the detection of dysplasia and assessment of the risk of colon cancer. The current surveillance strategy for dysplasia in IBD patients indicates white-light endoscopy with non-targeted biopsies. Despite the screening program, the high rate of colorectal cancer among IBD patients illustrates the need for better and more efficient techniques for dysplasia recognition. Classical chromoendoscopy and new digital techniques have provided promising results. In addition to the endoscopy techniques, stool and blood biomarkers are beneficial for the assessment of disease progress and disease monitoring. When used wisely and combined with the endoscopic methods, these techniques are promising in terms of the selection of patients for the early detection of dysplastic lesions and the prevention of inflammatory relapse.

INTRODUCTION
============

Although there has been significant therapeutic progress, inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis (UC), remains a challenge regarding its pathogenesis and long-term complications.

New concepts have emerged in the management of this disease, such as the "treat-to-target" concept, in which mucosal healing plays a key role in the assessments of the evolution, risk of recurrence and need for surgery.

Endoscopy is essential for the assessment of mucosal inflammation and plays a pivotal role in the analysis of mucosal healing in patients with IBD and in the detection of dysplasia and assessment of the risk of colon cancer. The current surveillance strategy for dysplasia in IBD patients indicates white-light endoscopy with non-targeted biopsies. The high rate of colorectal cancer (CRC) in IBD patients despite the screening program indicates the need for better and more efficient techniques for dysplasia recognition. Classical chromoendoscopy and new digital techniques have exhibited promising results.

Long-standing colitis represents an increased risk for the development of CRC in patients with IBD\[[@B1]\]. UC patients exhibit a 2.4-fold increased risk for the development of a colorectal cancer compared with the general population\[[@B2]\], and this risk increases with time by 2% after 10 years of disease, 8% at 20 years and 18% at 30 years\[[@B3]\]. The recognized risk factors for CRC are extensive colitis\[[@B4]\], early-age onset of the disease\[[@B5]\] (which supports the fact that longer duration inflammation is associated with a greater\[[@B6]\]), a family history of CRC\[[@B7]\] and concomitant primary sclerosing cholangitis\[[@B8]\]. Based on these factors, a personalized approach to each patient can be proposed and would involve individualized surveillance intervals depending on the risk factors of each patient\[[@B9]\].

Prevention represents the first step of treatment, and the regular follow-up of IBD patients through colonoscopy screenings for dysplasia reduces the mortality and morbidity of CRC by enabling action during earlier stages of tumors\[[@B10]\].

The detection of dysplasia represents the primary goal of colonoscopy surveillance in IBD patients, although it does not reduce the incidence of CRC to zero.

Although optimal surveillance strategies for CRC in IBD patients are not yet established, most gastroenterologists use white-light endoscopy with targeted and random biopsies. The recommendation is that colonoscopy surveillance should start 8-10 years after the diagnosis and encourages annual white-light examinations of the colonic mucosa, 4-quadrant non-targeted biopsies every 10 cm of the colon\[[@B9]\] that obtain at least 32 biopsies from the entire colon, and biopsy or resection of any suspicious lesion when possible. There is no significant difference in dysplasia detection between targeted and random biopsies, but the cost of targeted biopsies is lower\[[@B11]\].

However, this technique has its own disadvantages because flat and subtle dysplastic lesions are not readily identifiable, and active colonic inflammation can make the lesions difficult to interpret. Non-targeted biopsies will not always identify dysplasia because only a very small portion of the colonic mucosa is sampled. Moreover, this method is time-consuming and expensive.

An alternative to white-light colonoscopy (WLC) emerged with the introduction of chromoendoscopy (CME) to clinical practice. CME is an imaging technique that uses contrast agents to identify abnormalities of the colonic mucosa. Dysplastic lesions are better highlighted by the addition of two topical dyes, *i.e*., the contrast agent indigo carmine and the absorptive dye methylene blue (which is differentially taken up by normal colonic cells and neoplastic cells) and thus enable the endoscopist to differentiate between normal colonic mucosa and dysplastic mucosa. Polypoid lesions are easier to detect, and the dyes help the endoscopist delineate the lesion border\[[@B12]\].

In 2003, Kiesslich's clinical trial that included 165 UC patients revealed that more flat dysplasias\[[@B13]\] and intraepithelial neoplasias were identified by CME than by WLC. In another study of 102 IBD patients, Marion compared WLC with 4-quadrant random biopsies every 10 cm with targeted biopsies alone and CME with targeted biopsies and concluded that CME-targeted biopsies resulted in a notably higher rate of dysplasia identification than WLC with non-targeted biopsies\[[@B14]\].

Chromoendoscopy is able to detect dysplasia almost 7% more often than WLC, and the detection of flat dysplastic lesions increases by 27% with CME\[[@B15]\]. In 4 studies in which patients were examined by both WLE and CME, CME identified nearly twice as many dysplastic lesions.

All of these data have resulted in the acceptance of CME as an alternative to non-targeted biopsies; thus, in 2010, the AGA guidelines stated that CME can be used as an alternative to the actual dysplasia surveillance technique\[[@B16],[@B17]\], but well-established protocols are not yet available.

However, why is CME not the optimal technique for dysplasia surveillance in IBD patients? Why it is not routinely and widely used?

The main reasons that temper the enthusiasm for the adoption of CME as the optimal surveillance method are the bias effect of expert centers (it is less likely that every average endoscopist will obtain the same dysplasia detection rates as an expert center) and the lack of studies that demonstrate sustained benefits in terms of CRC morbidity and mortality. Other impediments include the increased time required for colonoscopy (CME increases the colonoscopy time by 9-12 min), the need to train endoscopists in this method and the lack of established quality measures.

With the recent advent of the new generation scopes, several image-enhancing techniques were introduced to routine practice to increase the sensitivity of the detection of dysplasia.

Narrow-band imaging (NBI) highlights the vascular and mucosal architectures with specialized light filters\[[@B18]\], but up-to-date studies have demonstrated no improvements in the recognition of dysplasia compared to WLC\[[@B19],[@B20]\].

NBI with targeted biopsies seem to result in a greater rate of dysplasia detection compared to WLE, but the difference is not statistically significant. Moreover, the miss rates of the two methods are comparable. The advantages of NBI could be that fewer biopsies are needed to diagnose neoplastic lesions, which might reduce costs, and a lower withdrawal time\[[@B21]\]. Although NBI and CME identified similar numbers of neoplastic lesions, the miss rate was higher for NBI\[[@B22]\].

Two other contrast-based technologies are available, *i.e*., flexible spectral imaging color enhancement (FICE-Fujifilm) and i-scan (Pentax). Both use a computer algorithm that modifies the white-light image\[[@B23]\]. However, there are no clinical trials that support their efficacies in detecting dysplasia in IBD patients, but it has been shown that these methods result in a 3-fold increase in polyp identification (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"})\[[@B24]\].

![Crohn's disease patient WL and flexible spectral imaging color enhancement. Better delineation of ileal edema and ulceration using FICE.](WJG-23-4324-g001){#F1}

![Ulcerative colitis-subtle lesions indicating recurrence getting more evident with flexible spectral imaging color enhancement.](WJG-23-4324-g002){#F2}

Recently, FICE has been increasingly used to improve videocapsule endoscopy (VCE) image quality and increase the detection of lesions of the small bowel, particularly erosions/ulcerations (Figure [3](#F3){ref-type="fig"}).

![Capsule images of jejunal ulceration in WL flexible spectral imaging color enhancement 1, 2, 3 and blue mode.](WJG-23-4324-g003){#F3}

This method is useful for better categorizing difficult-to-interpret small-bowel mucosal ulcerative lesions and can increase the diagnostic yield for Crohn's disease. However, care must be taken, patients should be selected, and the individual images should be evaluated only as part of a recording sequence because this technology can also result in the interpretation of artifacts as ulcerative lesions\[[@B25]\]. At the moment, in Crohn's disease, pan-enteric endoscopy using the colon capsule might be used to monitor patients and to stratify disease activity (due to the well-known limitations of clinical assessment) and can also be paramount in the guidance of therapeutic modifications. The combination of FICE and blue mode can result in the detection of even subtle lesions and therefore reduce the risk of recurrence\[[@B26]\].

An analysis of the literature did not reveal a superiority of the new methods over classical chromoendoscopy. Although the potential benefits of the newer optical and digital dye-less chromoendoscopy techniques are substantial, only the dye-based chromoendoscopy can currently be recommended for improving dysplasia detection in long-standing IBD patients\[[@B27]\]. However, digital chromoendoscopy has the potential to quantify disease activity and mucosal healing in IBD\[[@B27]\].

Other endoscopic imaging technologies for dysplasia identification are currently available. One such technology is confocal laser endomicroscopy (CLE), which offers microscopic imaging of the colonic mucosa in real-time\[[@B28]\]. Compared to CME, CLE with targeted biopsies detected almost twice as many intraepithelial neoplasias in a controlled trial of UC patients\[[@B29]\]. Moreover, CLE has the capacity to evaluate disease activity and identify characteristics that can be predictive of disease relapse\[[@B30]\]. Although it appears to be a promising method for detecting dysplasias and assessing IBD activity, CLE requires is time-consuming, requires perfect training, and requires larger studies to evaluate its efficacy; thus, for now, it remains research tool. Based on the same functional principle, endocytoscopy has the same deficiencies as CLE\[[@B31]\].

NBI results in similar dysplastic lesion detection rates as WLE, but it seems that NBI identifies more adenoma-like lesions, whereas WLE with random biopsies identifies more non-adenoma-like lesions\[[@B21]\]. The combination of these two techniques, which is used instinctively by many endoscopists, might improve the dysplasia detection rate. Inflammation in patients with IBD makes dysplasia diagnosis difficult. FICE can help differentiate dysplastic and non-dysplastic lesions\[[@B32]\] and can also predict the risk of recurrence, which allows us to modulate the treatment to gain better control of the disease.

When evaluating a new endoscopic imaging method, we look for the following criteria: efficiency, low cost, the ability to identify lesions, and being easy to learn. CME meets these criteria, although there is a small increase in the procedure duration. Compared with WLE with random biopsies, CME has been demonstrated to increase the rate of dysplasia detection. For CME to become the new standard surveillance strategy for dysplasia in IBD patients, additional clinical studies have to be performed. Because CME increases the rates of dysplasia detection and early recurrence, the benefits of this new technique are obvious. However, what are the limitations? The increase in procedure time and the decrease in accessibility (training is needed before newer endoscopic techniques can be used in our daily activity) seem to be the main restraining motifs that limit the use of these newer endoscopic methods mainly to tertiary centers. Regarding cost, we should note that, on one hand, there are greater costs associated with training and new endoscopes; on the other hand, the number of biopsies is lower, and the diagnostic yield is higher. Thus, the overall balance hangs on the side of new techniques.

In addition to endoscopy techniques, stool and blood biomarkers provide a helping hand for disease progress reduction and disease monitoring. When used wisely and combined with endoscopy, these methods exhibit promise in terms of the selection of patients for the early detection of dysplastic lesions and for the prevention of inflammatory relapse and can allow a personalized approach. We recommend the routine use of careful white light examination combined with NBI or FICE to target biopsies in all IBD patients.

Although we still do not have the perfect method, the available new endoscopic techniques offer promising results. The identification of a gold standard method for the evaluating disease evolution and preventing colon cancer in our IBD patients is only a matter of time.
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